Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3...
Covered in this story
What has happened since
- Bioage Labs Inc is down 75.1% since this was published, 85 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $BIOA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bioage Labs Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.